# Matthieu Allez

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/matthieu-allez/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,721 |
| Field | Inflammatory Bowel Disease |
| h-index | 84 |
| i10-index | 223 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5048807291 |
| ORCID iD | https://orcid.org/0000-0002-2012-7522 |
| Works | 550 |

## Researcher papers

- [Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial](https://scholariq.org/papers/ciclosporin-versus-infliximab-in-patients-with-severe-ulcerative-colitis/)
- [Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation](https://scholariq.org/papers/systemic-human-ilc-precursors-provide-a-substrate-for-tissue-ilc-differentiation/)
- [Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease](https://scholariq.org/papers/long-term-efficacy-and-safety-of-stem-cell-therapy-cx601-for-complex-perianal/)
- [Presentation and Long-Term Follow-up of Refractory Celiac Disease: Comparison of Type I With Type II](https://scholariq.org/papers/presentation-and-long-term-follow-up-of-refractory-celiac-disease-comparison-of/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial](https://scholariq.org/papers/ustekinumab-versus-adalimumab-for-induction-and-maintenance-therapy-in-biologic/)
- [Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting](https://scholariq.org/papers/management-of-patients-with-crohn-s-disease-and-ulcerative-colitis-during-the/)
- [Enteropathy associated T cell lymphoma in celiac disease: A large retrospective study](https://scholariq.org/papers/enteropathy-associated-t-cell-lymphoma-in-celiac-disease-a-large-retrospective/)
- [Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies](https://scholariq.org/papers/serologic-response-to-messenger-rna-coronavirus-disease-2019-vaccines-in/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)
- [Immunodeficiency and Autoimmune Disorders](https://scholariq.org/topics/immunodeficiency-and-autoimmune-disorders/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.